| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 144, Issue 5 1689-1695, Copyright © 1990 by American Association of Immunologists
ARTICLES |
RB Nussenblatt, RR Caspi, R Mahdi, CC Chan, F Roberge, O Lider and HL Weiner
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892.
The ability to prevent the expression of retinal SAg induced experimental autoimmune uveitis (EAU) in Lewis rats by oral administration of the SAg and SAg fragments was investigated. Oral administration of the SAg molecule prevented or markedly diminished the clinical appearance of SAg-induced disease as measured by ocular inflammation. Furthermore, oral administration of the SAg also markedly diminished uveitis induced by the uveitogenic M and N fragments of the SAg. M and N fragments were not effective in preventing SAg-induced EAU, although feeding the M fragment prevented disease induced by the M fragment. Oral administration of the SAg did not prevent myelin basic protein induced experimental autoimmune encephalomyelitis, whereas feeding myelin basic protein did. In vitro studies demonstrated a significant decrease in proliferative responses to the SAg in lymph node cells draining the site of immunization from fed vs nonfed animals. Furthermore, the addition of splenocytes from SAg-fed animals to cultures of a CD4+ SAg-specific cell line profoundly suppressed the cell line's response to the SAg, whereas these splenocytes had no effect on a purified protein derivative-specific cell line. The Ag- specific in vitro suppression was blocked by anti-CD8 antibody (OX-8) demonstrating that this suppression is dependent on CD8+ T-cells. These experiments demonstrate that Ag-specific immunomanipulation can be achieved in the EAU model by oral administration of the SAg and raise the possibility that such an approach may have practical clinical implications in uveitis as well as other human autoimmune diseases.
This article has been cited by other articles:
|
|
 |
|
  K. Nagatani, M. Dohi, Y. To, R. Tanaka, K. Okunishi, K. Nakagome, K. Sagawa, Y. Tanno, Y. Komagata, and K. Yamamoto Splenic Dendritic Cells Induced by Oral Antigen Administration Are Important for the Transfer of Oral Tolerance in an Experimental Model of Asthma J. Immunol., February 1, 2006; 176(3): 1481 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A P Gomes, H S Dua, L V Rizzo, M Nishi, A Joseph, and L A Donoso Ocular surface epithelium induces expression of human mucosal lymphocyte antigen (HML-1) on peripheral blood lymphocytes Br. J. Ophthalmol., February 1, 2004; 88(2): 280 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Dick A bird in the hand . . . Br. J. Ophthalmol., December 1, 2002; 86(12): 1324 - 1324. [Full Text]
|
|
|
|
|
|
A. D Dick, V. Sharma, and J. Liversidge Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy Br. J. Ophthalmol., August 1, 2001; 85(8): 1001 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-R. Jiang, N. Taylor, L. Duncan, A. D Dick, and J. V Forrester Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction Br. J. Ophthalmol., June 1, 2001; 85(6): 739 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Ogra, H. Faden, and R. C. Welliver Vaccination Strategies for Mucosal Immune Responses Clin. Microbiol. Rev., April 1, 2001; 14(2): 430 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Desvignes, N. Etchart, J. Kehren, I. Akiba, J.-F. Nicolas, and D. Kaiserlian Oral Administration of Hapten Inhibits In Vivo Induction of Specific Cytotoxic CD8+ T Cells Mediating Tissue Inflammation: A Role for Regulatory CD4+ T Cells J. Immunol., March 1, 2000; 164(5): 2515 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chung, S.-Y. Chang, and C.-Y. Kang Kinetic Analysis of Oral Tolerance: Memory Lymphocytes Are Refractory to Oral Tolerance J. Immunol., October 1, 1999; 163(7): 3692 - 3698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fukushima, K. Nishino, H. Yoshida, M. Takata, and H. Ueno Suppression of induction of experimental immune mediated blepharoconjunctivitis by tolerogenic conjugates of the antigen and monomethoxypolyethylene glycol Br. J. Ophthalmol., August 1, 1999; 83(8): 973 - 979. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Benson, S. S. Stuckman, K. L. Cox, R. M. Wardrop, I. E. Gienapp, A. H. Cross, J. L. Trotter, and C. C. Whitacre Oral Administration of Myelin Basic Protein Is Superior to Myelin in Suppressing Established Relapsing Experimental Autoimmune Encephalomyelitis J. Immunol., May 15, 1999; 162(10): 6247 - 6254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Laliotou and A. D Dick Modulating phenotype and cytokine production of leucocytic retinal infiltrate in experimental autoimmune uveoretinitis following intranasal tolerance induction with retinal antigens Br. J. Ophthalmol., April 1, 1999; 83(4): 478 - 485. [Abstract] [Full Text]
|
|
|
|
|
|
L. V. Rizzo, R. A. Morawetz, N. E. Miller-Rivero, R. Choi, B. Wiggert, C.-C. Chan, H. C. Morse III, R. B. Nussenblatt, and R. R. Caspi IL-4 and IL-10 Are Both Required for the Induction of Oral Tolerance J. Immunol., March 1, 1999; 162(5): 2613 - 2622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P GARSIDE, A M. MOWAT, and A KHORUTS Oral tolerance in disease Gut, January 1, 1999; 44(1): 137 - 142. [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, W. Jin, M. Cook, H. L. Weiner, and S. M. Wahl Oral Delivery of Group A Streptococcal Cell Walls Augments Circulating TGF-{beta} and Suppresses Streptococcal Cell Wall Arthritis J. Immunol., December 1, 1998; 161(11): 6297 - 6304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yoshino, M. Ohsawa, and M. Sagai Diesel Exhaust Particles Block Induction of Oral Tolerance in Mice J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 679 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
S. Yoshino Treatment with an Anti-IL-4 Monoclonal Antibody Blocks Suppression of Collagen-Induced Arthritis in Mice by Oral Administration of Type II Collagen J. Immunol., March 15, 1998; 160(6): 3067 - 3071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K A WILLIAMS Oral administration of antigen in the treatment of eye disease Br. J. Ophthalmol., September 1, 1997; 81(9): 714 - 715. [Full Text] [PDF]
|
|
|
|
|
|
D. Ma, J. Mellon, and J. Y Niederkorn Oral immunisation as a strategy for enhancing corneal allograft survival Br. J. Ophthalmol., September 1, 1997; 81(9): 778 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bergerot, C. Ploix, J. Petersen, V. Moulin, C. Rask, N. Fabien, M. Lindblad, A. Mayer, C. Czerkinsky, J. Holmgren, et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes PNAS, April 29, 1997; 94(9): 4610 - 4614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Prakken, R. van der Zee, S. M. Anderton, P. J. S. van Kooten, W. Kuis, and W. van Eden Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis PNAS, April 1, 1997; 94(7): 3284 - 3289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Laliotou, J. Liversidge, J. V Forrester, and A. D Dick Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific Br. J. Ophthalmol., January 1, 1997; 81(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Blanas, F. R. Carbone, J. Allison, J. F. A. P. Miller, and W. R. Heath Induction of Autoimmune Diabetes by Oral Administration of Autoantigen Science, December 6, 1996; 274(5293): 1707 - 11709. [Abstract] [Full Text]
|
|
|
|
|
|
C McMenamin, C Pimm, M McKersey, and P. Holt Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells Science, September 23, 1994; 265(5180): 1869 - 1871. [Abstract] [PDF]
|
|
|
|
|
|
D. Trentham, R. Dynesius-Trentham, E. Orav, D Combitchi, C Lorenzo, K. Sewell, D. Hafler, and H. Weiner Effects of oral administration of type II collagen on rheumatoid arthritis Science, September 24, 1993; 261(5129): 1727 - 1730. [Abstract] [PDF]
|
|
|
|
|
|
H. Weiner, G. Mackin, M Matsui, E. Orav, S. Khoury, D. Dawson, and D. Hafler Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis Science, February 26, 1993; 259(5099): 1321 - 1324. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
